autologous dendritic cells + autologous central memory T cells + LHRH agonists

This therapeutic regimen is a **combination immunotherapy and hormonal therapy approach** that pairs three modalities: - **Autologous dendritic cells (DCs):** Patient-derived DCs are isolated and activated ex vivo, commonly loaded with tumor antigens to stimulate an anti-tumor immune response. Their primary role is to present tumor-derived antigens and activate T cells, particularly cytotoxic and memory subsets, leading to robust and antigen-specific immune responses[3][5][7]. - **Autologous central memory T cells (CM T cells):** These are patient-derived T cells sorted for the central memory phenotype (typically CD45RA–CD45R0+CCR7+CD62L+) and expanded/activated ex vivo. In cancer immunotherapy, they are often co-cultured with activated antigen-loaded DCs before being reinfused. CM T cells confer enhanced tumor-specific cytotoxicity and longer persistence, especially when re-stimulated by dendritic cells[5]. - **LHRH agonists (luteinizing hormone-releasing hormone agonists):** These are synthetic analogs (such as goserelin, leuprolide, triptorelin) that suppress the pituitary-gonadal axis, resulting in medical castration by reducing sex steroid hormones. In oncology, they are utilized for hormone-dependent malignancies (notably prostate and breast cancer) and can also exert direct inhibitory effects on tumors expressing LHRH receptors[2][4][6]. The expected mechanism is a synergistic attack on cancer: immune activation and memory via DCs and T cells, with concurrent reduction in hormonal stimulation supporting tumor growth via LHRH agonists. This combination is considered investigational and primarily explored in refractory or metastatic cancer settings, e.g. advanced breast or prostate cancer[3][5][4].